Published in Oxid Med Cell Longev on February 05, 2016
Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes. Oxid Med Cell Longev (2010) 0.97
Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev (2010) 0.82
Role of receptor for advanced glycation end products (RAGE) in liver disease. Eur J Med Res (2015) 0.78
Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension. Oxid Med Cell Longev (2010) 0.78
Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Mol Med (2015) 0.77
Advanced protein glycosylation in diabetes and aging. Annu Rev Med (1995) 4.13
Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest (1994) 3.70
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des (2005) 2.06
Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.86
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol (1993) 1.60
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med (2010) 1.43
Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol (2009) 1.30
High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol (2005) 1.27
AGE-RAGE system and carcinogenesis. Curr Pharm Des (2008) 1.24
Testosterone concentration in young patients with diabetes. Diabetes Care (2008) 1.11
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs (2008) 1.10
Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des (2008) 1.07
Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis (2009) 1.01
Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab (2009) 0.99
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res (2009) 0.95
XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products. Eur J Pharmacol (2009) 0.95
Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med (2007) 0.92
Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res (2008) 0.90
Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging (2008) 0.88
Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res (2007) 0.87
Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis (1998) 0.85
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun (2009) 0.84
Cardiovascular disease: what's all the AGE/RAGE about? Cardiovasc Hematol Disord Drug Targets (2010) 0.84
Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed (2010) 0.83
Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets (2010) 0.80